Bio-Path Holdings, Inc. · OTC:BPTH

Bio-Path — Investor Presentation (July 2017)

22 slides from Bio-Path's investor presentation, July 2017

  1. Slide 1: Company Presentation July 2017

    Slide 1: Company Presentation July 2017

    Company Presentation July 2017 “A new path in DNA-powered medicine” 1

  2. Slide 2: Forward Looking Statements

    Slide 2: Forward Looking Statements

    Forward Looking Statements This Presentation contains forward-looking statements with respect to business conducted by Bio-Path Holdings, Inc. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will

  3. Slide 3: DNAbilize Technology

    Slide 3: DNAbilize Technology

    DNAbilize™ Technology ✓ Enables the development and delivery of systemic antisense DNA treatments for a broad spectrum of cancers including hematological malignancies, solid tumors, as well as diseases outside of cancer ➢ has been the only technology in therapeutic applications that has shown no evi

  4. Slide 4: Investment Highlights

    Slide 4: Investment Highlights

    Investment Highlights • Advanced oligonucleotide therapeutics with high efficiency delivery Broad Vision, Focused • New composition and methods of use patents filed to cover DNAbilize™ Strategy technology solely owned by Bio-Path • Lead candidate prexigebersen in Phase II for acute myeloid leukemia

  5. Slide 5: DNAbilize Antisense and Technology Profile: A Targeted Method for Treating Disease

    Slide 5: DNAbilize Antisense and Technology Profile: A Targeted Method for Treating Disease

    DNAbilize™ Antisense and Technology Profile: A Targeted Method for Treating Disease ➢ Antisense - molecules that interfere with the process of producing proteins inside cells (RNAi) ➢ Does not use a toxic agent to kill cells, but blocks production of proteins ➢ Advantage of specificity because it ta

  6. Slide 6: DNAbilize Technology Summary

    Slide 6: DNAbilize Technology Summary

    DNAbilize™ Technology Summary DNAbilize™ Technology is a proprietary antisense and delivery platform that solves the antisense industry dilemma SAFE: No toxicity from the DNA modification or the lipid delivery, no platelet or hepatic toxicity SYSTEMIC: Allows for systemic distribution via IV infusio

  7. Slide 7: Clinical Pipeline

    Slide 7: Clinical Pipeline

    Clinical Pipeline Target Indications Preclinical IND Phase I Phase II Prexigebersen (BP1001) AML* Prexigebersen (BP1001) CML* Prexigebersen Solid (BP1001) tumors BP1002 (Liposomal Bcl2) Lymphoma DNAbilize™ Technology Ready to out-license *Prexigebersen (BP1001) has received orphan drug designation f

  8. Slide 8: Continuing Improvement in Product Design and Manufacturing

    Slide 8: Continuing Improvement in Product Design and Manufacturing

    Continuing Improvement in Product Design and Manufacturing Scale up 2nd Going Forward CMC’s IND Manufacturing Development from initial Generation • Lyo process Lead Product batch size Formulation • Capacity • New assays • Process • High oligo • Lyo cycle • Oligo loading properties • Capacity increas

  9. Slide 9: Manufacturing Improvements

    Slide 9: Manufacturing Improvements

    Manufacturing Improvements ➢ Through our dose-escalating Phase 1 trial we upgraded our supplier base with the goal of increased capability and capacity ➢ Improved capabilities and operating efficiencies affected important drug properties, result being the need to re-optimize manufacturing ➢ We are d

  10. Slide 10: DNAbilize Lead Target and Indications: Grb2 and Myeloid Leukemia

    Slide 10: DNAbilize Lead Target and Indications: Grb2 and Myeloid Leukemia

    DNAbilize™ Lead Target and Indications: Grb2 and Myeloid Leukemia Prexigebersen (BP1001) is an antisense DNA to the bridging protein Grb2 ❖ Ideal target for myeloid leukemia because it shuts down the Ras pathway in receptor activated myeloid cells without exerting adverse effects on Ras signaling th

  11. Slide 11: Summary of Phase I Monotherapy Clinical Trial Results for Prexigebersen

    Slide 11: Summary of Phase I Monotherapy Clinical Trial Results for Prexigebersen

    Summary of Phase I Monotherapy Clinical Trial Results for Prexigebersen ➢ AML, CML, & MDS Patients Refractory or Resistant to Current Therapies ➢ Patients averaged 6 prior therapies ➢ Dose escalating treatment cycle, 8 doses over 4 weeks, up to 90 mg/m2 ➢ Average reduction in circulating blasts was

  12. Slide 12: Prexigebersen Down-regulates Grb2 Protein in Target Cells

    Slide 12: Prexigebersen Down-regulates Grb2 Protein in Target Cells

    Prexigebersen Down-regulates Grb2 Protein in Target Cells Grb2 levels decreased in 11 of 13 patient samples by end of treatment (EOT) pErk levels decreased in 7 of 13 patient samples by EOT 2 2 NS1 = no sample collected 2Fewer cells used in analysis because sample had less cells 12

  13. Slide 13: Response to Treatment for Blast Crisis CML and Stable Disease in AML

    Slide 13: Response to Treatment for Blast Crisis CML and Stable Disease in AML

    Response to Treatment for Blast Crisis CML and Stable Disease in AML • Patient 002: 32 year-old, Hispanic male with myeloid blast crisis of CML • Prior therapies consisted of: ― Gleevec ― Dasatinib ― Nilotinib ― DCC-2036 ― Cytarabine/Fludarabine/ ― Dasatinib/Gemtuzumab ― PHA-739358 ― Clofarabine/Das

  14. Slide 14: Safety Segment Phase II Prexigebersen + LDAC Combination Therapy Results

    Slide 14: Safety Segment Phase II Prexigebersen + LDAC Combination Therapy Results

    Safety Segment Phase II Prexigebersen + LDAC Combination Therapy Results Relapsed/refractory AML patients - 3 evaluable patients in each of 2 cohorts - Dose 60 mg/m2 and 90 mg/m2 respectively - Received drug 2x week for 4 weeks 5 of 6 patients responded: - 3 patients achieved complete remission - 2

  15. Slide 15: Ongoing Phase II Efficacy Trial Design for AML Prexigebersen Combination Therapy

    Slide 15: Ongoing Phase II Efficacy Trial Design for AML Prexigebersen Combination Therapy

    Ongoing Phase II Efficacy Trial Design for AML Prexigebersen Combination Therapy • Safety segment completed, demonstrated no negative synergies using prexigebersen together with frontline therapy (LDAC) – Treatment of de novo AML patients who are induction therapy ineligible and unfit for a stem cel

  16. Slide 16: Advances in the CML Program

    Slide 16: Advances in the CML Program

    Advances in the CML Program • Presentation at the 58th American Society of Hematology Annual Meeting: – BP1001, a Novel Therapeutic for Chronic Myelogenous Leukemia • Prexigebersen decreased the proliferation of Gleevec® (imatinib)-resistant CML cells in a dose-dependent manner • Prexigebersen pretr

  17. Slide 17: Prexigebersen Treatment Paradigm

    Slide 17: Prexigebersen Treatment Paradigm

    Prexigebersen Treatment Paradigm • Frontline therapy for de novo AML patients who are induction therapy ineligible and unfit for a stem cell transplant – Prexigebersen combination with LDAC – Current response rate frontline therapy alone less than 20% – Prexigebersen to improve response rates signif

  18. Slide 18: Preclinical Pipeline

    Slide 18: Preclinical Pipeline

    Preclinical Pipeline Validating DNAbilize™ with Key Opinion Leaders: • Establishing prexigebersen in triple negative and inflammatory breast cancer and advanced ovarian cancer with the MD Anderson Cancer Center – Advances in liposome properties enhancing solid tumor outcomes • Developing clinical an

  19. Slide 19: Achievements and Upcoming Milestones

    Slide 19: Achievements and Upcoming Milestones

    Achievements and Upcoming Milestones Recent Accomplishments: Value propositions being advanced: • Potential for switch to registration trial for  On target to complete enrollment of the accelerated approval after the interim analysis first 19 patients for the interim analysis for of the first 19 pa

  20. Slide 20: Leadership

    Slide 20: Leadership

    Leadership Peter Nielsen Co-Founder, President, Chief Executive Officer and Chief Financial Officer • Officer and Director since founding Company in 2007 • Manufacturing development and evolution of engineered product design Ulrich Mueller, PhD Chief Operating Officer • Previously Vice President at

  21. Slide 21: Scientific Advisory Board

    Slide 21: Scientific Advisory Board

    Scientific Advisory Board Jorge Cortes, M.D. Chairman • M.D. from la Facultad de Medicina, Universidad Nacional Autónoma de México • Jane and John Justin Distinguished Chair in Leukemia Research, Chief of the AML and CML sections, and Deputy Chair of the Department of Leukemia at The University of T

  22. Slide 22: IP and Financial Snapshot

    Slide 22: IP and Financial Snapshot

    IP and Financial Snapshot Intellectual Property • Original patents licensed from MD Anderson • New composition and methods of use patents filed to cover DNAbilize™ technology, solely owned by Bio-Path Financial Snapshot • Ticker: NASDAQ: BPTH • Cash: $7.1 million as of March 31, 2017 • $10 million r

Source: Internet Archive copy of biopathholdings.com

More decks from Bio-Path Holdings, Inc.

All 11 Bio-Path decks